Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors
Autor(a) principal: | |
---|---|
Data de Publicação: | 2006 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Memórias do Instituto Oswaldo Cruz |
Texto Completo: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762006000200009 |
Resumo: | The natural lignans veraguensin and grandisin have been reported to be active against Trypanosoma cruzi bloodstream forms. Aiming at the total synthesis of these and related compounds, we prepared three 2-arylfurans and eight 2,5-diarylfurans. They were evaluated for their potential as T. cruzi trypanothione reductase (TR) inhibitors as well against the parasite's intracellular (amastigote) and bloodstream (trypomastigote) forms. Compound 12 was the most effective against TR with an IC50 of 48.5 µM while 7 and 14 were active against amastigotes, inhibiting the parasite development by 60% at 20 µg/ml (59 and 90 µM, respectively). On the other hand, none of the compounds was significantly active against the parasite bloodstream forms even at 250 µg/ml (0.6-1.5 mM). |
id |
FIOCRUZ-4_67bdf1ef7dca952ae9b2f7c184fdf3e8 |
---|---|
oai_identifier_str |
oai:scielo:S0074-02762006000200009 |
network_acronym_str |
FIOCRUZ-4 |
network_name_str |
Memórias do Instituto Oswaldo Cruz |
spelling |
Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitorstropical diseasesChagas diseasearylfuranstrypanothione reductaseThe natural lignans veraguensin and grandisin have been reported to be active against Trypanosoma cruzi bloodstream forms. Aiming at the total synthesis of these and related compounds, we prepared three 2-arylfurans and eight 2,5-diarylfurans. They were evaluated for their potential as T. cruzi trypanothione reductase (TR) inhibitors as well against the parasite's intracellular (amastigote) and bloodstream (trypomastigote) forms. Compound 12 was the most effective against TR with an IC50 of 48.5 µM while 7 and 14 were active against amastigotes, inhibiting the parasite development by 60% at 20 µg/ml (59 and 90 µM, respectively). On the other hand, none of the compounds was significantly active against the parasite bloodstream forms even at 250 µg/ml (0.6-1.5 mM).Instituto Oswaldo Cruz, Ministério da Saúde2006-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762006000200009Memórias do Instituto Oswaldo Cruz v.101 n.2 2006reponame:Memórias do Instituto Oswaldo Cruzinstname:Fundação Oswaldo Cruzinstacron:FIOCRUZ10.1590/S0074-02762006000200009info:eu-repo/semantics/openAccessOliveira,Renata B deVaz,Aline BMAlves,Rosana OLiarte,Daniel BDonnici,Claudio LRomanha,Alvaro JZani,Carlos Leng2020-04-25T17:49:33Zhttp://www.scielo.br/oai/scielo-oai.php0074-02761678-8060opendoar:null2020-04-26 02:13:42.359Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruztrue |
dc.title.none.fl_str_mv |
Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors |
title |
Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors |
spellingShingle |
Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors Oliveira,Renata B de tropical diseases Chagas disease arylfurans trypanothione reductase |
title_short |
Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors |
title_full |
Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors |
title_fullStr |
Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors |
title_full_unstemmed |
Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors |
title_sort |
Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors |
author |
Oliveira,Renata B de |
author_facet |
Oliveira,Renata B de Vaz,Aline BM Alves,Rosana O Liarte,Daniel B Donnici,Claudio L Romanha,Alvaro J Zani,Carlos L |
author_role |
author |
author2 |
Vaz,Aline BM Alves,Rosana O Liarte,Daniel B Donnici,Claudio L Romanha,Alvaro J Zani,Carlos L |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Oliveira,Renata B de Vaz,Aline BM Alves,Rosana O Liarte,Daniel B Donnici,Claudio L Romanha,Alvaro J Zani,Carlos L |
dc.subject.por.fl_str_mv |
tropical diseases Chagas disease arylfurans trypanothione reductase |
topic |
tropical diseases Chagas disease arylfurans trypanothione reductase |
dc.description.none.fl_txt_mv |
The natural lignans veraguensin and grandisin have been reported to be active against Trypanosoma cruzi bloodstream forms. Aiming at the total synthesis of these and related compounds, we prepared three 2-arylfurans and eight 2,5-diarylfurans. They were evaluated for their potential as T. cruzi trypanothione reductase (TR) inhibitors as well against the parasite's intracellular (amastigote) and bloodstream (trypomastigote) forms. Compound 12 was the most effective against TR with an IC50 of 48.5 µM while 7 and 14 were active against amastigotes, inhibiting the parasite development by 60% at 20 µg/ml (59 and 90 µM, respectively). On the other hand, none of the compounds was significantly active against the parasite bloodstream forms even at 250 µg/ml (0.6-1.5 mM). |
description |
The natural lignans veraguensin and grandisin have been reported to be active against Trypanosoma cruzi bloodstream forms. Aiming at the total synthesis of these and related compounds, we prepared three 2-arylfurans and eight 2,5-diarylfurans. They were evaluated for their potential as T. cruzi trypanothione reductase (TR) inhibitors as well against the parasite's intracellular (amastigote) and bloodstream (trypomastigote) forms. Compound 12 was the most effective against TR with an IC50 of 48.5 µM while 7 and 14 were active against amastigotes, inhibiting the parasite development by 60% at 20 µg/ml (59 and 90 µM, respectively). On the other hand, none of the compounds was significantly active against the parasite bloodstream forms even at 250 µg/ml (0.6-1.5 mM). |
publishDate |
2006 |
dc.date.none.fl_str_mv |
2006-03-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762006000200009 |
url |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762006000200009 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0074-02762006000200009 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Instituto Oswaldo Cruz, Ministério da Saúde |
publisher.none.fl_str_mv |
Instituto Oswaldo Cruz, Ministério da Saúde |
dc.source.none.fl_str_mv |
Memórias do Instituto Oswaldo Cruz v.101 n.2 2006 reponame:Memórias do Instituto Oswaldo Cruz instname:Fundação Oswaldo Cruz instacron:FIOCRUZ |
reponame_str |
Memórias do Instituto Oswaldo Cruz |
collection |
Memórias do Instituto Oswaldo Cruz |
instname_str |
Fundação Oswaldo Cruz |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
repository.name.fl_str_mv |
Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruz |
repository.mail.fl_str_mv |
|
_version_ |
1669937695812485120 |